Jane Street Group LLC Makes New Investment in Q32 Bio Inc. (NASDAQ:QTTB)

Jane Street Group LLC acquired a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 16,437 shares of the company’s stock, valued at approximately $733,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp boosted its stake in Q32 Bio by 35.5% in the 3rd quarter. State Street Corp now owns 110,164 shares of the company’s stock valued at $4,916,000 after purchasing an additional 28,865 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Q32 Bio in the third quarter valued at about $3,422,000. Eventide Asset Management LLC bought a new position in Q32 Bio during the third quarter worth about $8,478,000. MetLife Investment Management LLC bought a new position in Q32 Bio during the third quarter worth about $159,000. Finally, BNP Paribas Financial Markets raised its stake in Q32 Bio by 199.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock worth $58,000 after purchasing an additional 864 shares in the last quarter. Institutional investors and hedge funds own 31.32% of the company’s stock.

Analyst Ratings Changes

QTTB has been the topic of a number of analyst reports. Raymond James restated an “outperform” rating and set a $22.00 target price (down previously from $90.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Guggenheim downgraded Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Oppenheimer dropped their price objective on Q32 Bio from $80.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler cut their target price on Q32 Bio from $85.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Finally, Leerink Partners restated a “market perform” rating and issued a $9.00 price target (down previously from $68.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Q32 Bio Trading Up 0.3 %

Shares of QTTB opened at $3.45 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53. Q32 Bio Inc. has a 52-week low of $3.02 and a 52-week high of $53.79. The firm has a market cap of $42.02 million, a price-to-earnings ratio of -0.24 and a beta of -0.46. The business’s fifty day moving average is $25.33 and its 200-day moving average is $32.40.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.